Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype

Hematological Oncology

Volumn 25, Issue 1, 2007, Pages 1-5

  Palmieri, Salvatore ^a,d   Ferrara, Felicetto ^a   Leoni, Franco ^b   Ciolli, Stefania ^b   Pollio, Filiberto ^a   D'Amico, Maria Rosaria ^a   Celentano, Maria ^a   Viola, Assunta ^a   Vicari, Laura ^a   Izzo, Barbara ^c   Pane, Fabrizio ^c  

^a CARDARELLI HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d NONE   (Italy)

Author keywords

Acute myeloid leukaemia; Autologous transplantation; FLT3 mutations; Prognostic relevance

Indexed keywords

AMPHOTERICIN B; BUSULFAN; CD135 ANTIGEN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; LACTATE DEHYDROGENASE; MITOXANTRONE; PHENYTOIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; ASPERGILLOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CANDIDIASIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MUTATION; MYELOABLATIVE CONDITIONING; NEUTROPENIA; OSTEOBLAST; PRIORITY JOURNAL; PROGNOSIS;

ACUTE DISEASE; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MUTATION; MYELOABLATIVE AGONISTS; PROGNOSIS; REMISSION INDUCTION; SURVIVAL ANALYSIS; TANDEM REPEAT SEQUENCES; TRANSPLANTATION, AUTOLOGOUS;

EID: 33947508092     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.794     Document Type: Article

References (32)

1. Ferrara F. Unanswered questions in acute myeloid leukaemia. Lancet Oncol 2004; 5: 443-450.
2. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
3. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/ Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083.
4. Mrozek K, Heinonen K, Bloomfield CD. Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract Res Clini Haematol 2001; 14: 19-47.
5. Grimwade D. The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001; 14: 497-529.
6. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-4336.
7. Ferrara F, Palmieri S, Mele G. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukaemia. Haematologica 2004; 89: 998-1008.
8. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-1759.
9. Boissel N, Cayuela JM, Preudhomme C, et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia 2002; 16: 1699-1704.
10. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002; 100: 4372-4380.
11. Ciolli S, Vannucchi AM, Leoni F, et al. Internal tandem duplications of Flt3 gene (Flt3/ITD) predicts a poor post-remission outcome in adult patients with acute non-promyelocytic leukemia. Leuk Lymphoma 2004; 45: 73-78.
12. Kottaridis PD, Gale RE, Linch D. Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia. Leuk Lymphoma 2003; 44: 905-913.
13. Sebastio L, Ferrara F, Vicari L, et al. Simultaneous occurrence of tetrasomy 21 and trisomy 8 in a patient with early blastic metamorphosis of chronic myeloproliferative disorder. Am J Hematol 1995; 50: 49-52.
14. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Int Med 1985; 105: 620-625.
15. Ferrara F, Morabito F, Martino B, et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous All-trans-Retinoic acid and chemotherapy. J Clin Oncol 2000; 18: 1295-1300.
16. Ferrara F, D'Arco AM, De Simone M, et al. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukaemia. Haematologica 2005; 90: 776-784.
17. Ferrara F, Palmieri S, De Simone M, et al. High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia. Br J Haematol 2005; 128: 234-241.
18. Ferrara F, Palmieri S, Annunziata M, et al. Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukaemia aged over 60 years undergoing autologous stem cell transplantation. Bone Marrow Transplant 2004; 34: 573-576.
19. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
21. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59-66.
22. Schnittger S, Schoch C, Kern W, et al. FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia. Acta Haematol 2004; 112: 68-78.
23. Scholl S, Loncarevic IF, Krause C, et al. Minimal residual disease based on patient specific FLT3-ITD and -ITT mutations in acute myeloid leukemia. Leuk Res 2005; 29: 849-853.
24. Levis M, Small D. FLT3 tyrosine kinase inhibitors. Int J Hematol 2005; 82: 100-107.
25. Sternberg DW, Licht JD. Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges. Curr Opin Hematol 2005; 12: 7-13.
26. Yoshimoto G, Nagafuji K, Miyamoto T, et al. FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2005; 36: 977-983.
27. Gale RM, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients,excluding acute promyelocytic leukemia, from the UK MRCAML10 and 12 trials. Blood 2005; 106: 3658-3665.
28. Gorin N. Autologous stem cell transplantation for adult acute leukemia. Curr Opin Oncol 2002; 14: 152-159.
29. Linker CA. Autologous stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplant 2003; 31: 731-738.
30. Mathews V, DiPersio JF. Stem cell transplantation in acute myelogenous leukemia in first remission: what are the options? Curr Hematol Rep 2004; 3: 235-241.
31. Nathan PC, Sung L, Crump M, Beyene J. Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis. J Natl Cancer Inst 2004; 96: 38-45.
32. Breems DA, Lowenberg B. Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia. Br J Haematol 2005; 128: 59-65.